FRM
LEGN icon

Fox Run Management’s Legend Biotech LEGN Stock Holding History

Fox Run Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,806
Closed -$452K – 1086
2025
Q4 		$452K Buy
20,806
+863
+4% +$24.7K 0.07% 538
2025
Q3 		$650K Buy
+19,943
New +$736K 0.1% 390
2025
Q2 		– Sell
-11,305
Closed -$384K – 1059
2025
Q1 		$384K Sell
11,305
-1,619
-13% -$58.1K 0.06% 597
2024
Q4 		$421K Buy
+12,924
New +$535K 0.08% 497

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.44B AUM 18.47% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fox Run Management's LEGN Position: Q1 2026 in Review

Fox Run Management sold out of Legend Biotech (LEGN) in Q1 2026, closing a stake of 20,806 shares — an estimated $452K sold.

Fox Run Management first reported a position in LEGN in Q4 2024 and held it in 4 quarters. The position peaked at $650K in Q3 2025. 191 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Fox Run Management reported no remaining Legend Biotech position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 20,806 Legend Biotech shares in Q1 2026, an estimated $452K.
  • Fox Run Management first reported a position in Legend Biotech in Q4 2024 and held it in 4 quarters.
  • Fox Run Management's Legend Biotech position peaked at $650K in Q3 2025.
  • 191 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.